Net Loss Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2023

Net Loss Per Share of Common Stock

Schedule of computation of basic and diluted earnings per share

	Year ended December 31,
	2023		2022
Basic and diluted net loss per share of common stock:
Net loss attributable to Onconova Therapeutics, Inc.	$	(18,948,000)	$	(18,964,000)
Weighted average shares of common stock outstanding		20,988,863		20,908,235
Net loss per share of common stock—basic and diluted	$	(0.90)	$	(0.91)

Schedule of antidilutive securities which have been excluded from the computation of diluted weighted average shares outstanding

	December 31,
	2023	2022
Warrants	307,716	344,990
Stock options	2,311,021	1,397,763
	2,618,737	1,742,753